In long-acting injectable microsphere lines for leuprolide acetate, octreotide acetate, and risperidone, the LACTEL 75:25 DL-PLG (B6007-1) biomedical PLGA copolymer is dissolved in dichloromethane at 10–20 wt% and combined with an aqueous peptide phase through a rotor-stator mixer at 5,000–20,000 rpm. The primary emulsion is transferred into an aqueous poly(vinyl alcohol) solution at 0.1–1.0% w/w and subjected to secondary emulsification in a Silverson L5M-A or equivalent high-shear mixer at 8,000–15,000 rpm for 2–10 minutes. Solvent extraction is conducted in water or aqueous isopropanol at 10–20°C for 3–6 hours; the residual dichloromethane content is driven below 600 ppm to satisfy USP <467> and ICH Q3C(R8) Class 2 limits for parenteral products. The acid-terminated 75:25 DL-PLG composition accelerates hydrolytic chain scission relative to ester-capped grades, so the in vitro release profile in phosphate-buffered saline at 37°C can exhibit a lag phase of 1–3 weeks followed by an erosion phase, depending on drug loading and particle size; B6007-1-specific release must be confirmed by lot release testing. Control limits for injectable microspheres are commonly set at a Dv50 of 20–100 μm, because particles above 100 μm trap acidic degradation products and develop internal autocatalytic erosion before surface release. Particle size is confirmed by laser diffraction per ISO 13320:2020. Residual poly(vinyl alcohol) on the microsphere surface is measured gravimetrically or by colorimetric iodine method, with target below 0.5 wt%. If the solvent removal rate is accelerated too quickly, the glass transition temperature of residual dichloromethane-plasticized polymer is depressed below process temperature and surface pitting appears. Published production-scale data for this specific B6007-1 lot is limited, but glass transition temperature by differential scanning calorimetry is expected near 45–50°C when solvent-free according to ASTM D3418-21.

Why Does Acid-Terminated 75:25 DL-PLG Constrain Injection Vehicle Selection for In Situ Depots?

The selection of N-methyl-2-pyrrolidone as the primary solvent for B6007-1 in in situ forming depots is constrained by the polymer’s acid end groups and amorphous 75:25 DL-lactide/glycolide sequence distribution. A typical flowable depot is prepared at 40–60 wt% polymer in N-methyl-2-pyrrolidone, with dimethyl sulfoxide or triacetin added as a viscosity modifier. Pre-drying of the polymer at 25–30°C under vacuum below 0.1 mbar for 24–48 hours is required when ambient RH exceeds 60%, because residual water in the organic solvent promotes hydrolytic molecular weight loss before the depot is injected. The main processing conflict is maintaining injectability through a 21–25 G needle while limiting the burst release caused by rapid N-methyl-2-pyrrolidone exchange. Dynamic viscosity of a 50 wt% solution at 25°C and shear rate 10 s⁻¹ is generally in the range of 1–10 Pa·s, but batch-to-batch variation in inherent viscosity from 0.55–0.75 dL/g in chloroform at 25°C shifts needle force and depot shape. When injected into phosphate-buffered saline or subcutaneous tissue, the solvent diffuses outward faster than water diffuses inward; if the polymer-rich skin forms too early, the depot can crack during muscle flexion and release drug unpredictably. Addition of low-molecular-weight PLGA at 10–20 wt% of total polymer is reported to slow phase inversion and reduce the 24-hour burst from 30–50% to below 15% in pilot studies, although B6007-1-specific data is limited. Residual N-methyl-2-pyrrolidone is controlled by ICH Q3C(R8) permitted daily exposure, not by a simple weight-percentage limit. Because the 75:25 DL-PLG matrix degrades by autocatalytic acid generation, microenvironments near the depot core can drop below pH 6.5 after 2–4 weeks; this is relevant for acid-labile peptide payloads. Filtration of the final solution is not possible after polymer dissolution, so aseptic preparation using ISO 14644-1:2015 Class 5 conditions and depyrogenated solvent is required.

When PLGA nanoparticles for nucleic acid and vaccine antigen delivery are produced by microfluidic nanoprecipitation, B6007-1 is dissolved in acetonitrile or acetone at 5–20 mg/mL and mixed with an aqueous payload phase at flow rate ratios from 1:5 to 1:20. Total flow rates of 1–10 mL/min through a staggered herringbone mixer or coaxial glass capillary yield particles with Z-average diameter of 80–250 nm and polydispersity index below 0.2 as measured by dynamic light scattering per ISO 22412:2017. The acid-terminal carboxylate groups on B6007-1 produce zeta potentials of roughly −20 to −40 mV in 1 mM potassium chloride at 25°C, which reduces aggregation but can destabilize cationic lipid or polyethylenimine complexes used for mRNA delivery. Residual acetonitrile is removed by tangential flow filtration or rotary evaporation and is controlled below 410 ppm as a Class 2 solvent under ICH Q3C(R8). Scale-up from chip-based systems to continuous flow reactors is limited by the need to maintain identical mixing time and solvent polarity across channels wider than 500 μm. Published data for this specific acid-terminated 75:25 DL-PLG configuration is limited; most published formulations use ester-capped PLGA, so the effect of higher acid end-group density on nucleic acid payload stability must be verified by gel electrophoresis and cell transfection assay before locking the B6007-1 formulation.

Ophthalmic Matrix Reservoirs Require Hot-Melt Extrusion Below the Amorphous Softening Threshold

Hot-melt extrusion of B6007-1 for intravitreal dexamethasone reservoirs requires extrusion temperatures between 110°C and 140°C to avoid the rapid hydrolytic chain scission observed above 150°C. A 16 mm twin-screw extruder with L/D ratio 25:1 and screw speeds of 25–50 rpm is used to minimize shear heating; a single pass at 140°C can reduce molecular weight by more than 10%, so melt temperature is monitored by infrared thermocouple at the die. The polymer is amorphous, but residual lactide monomer or oligomeric cyclic ester can crystallize if the material was stored at high humidity. Crystallinity by differential scanning calorimetry should remain below 2% when tested per ASTM D3418-21, because semicrystalline regions scatter light and create non-uniform drug distribution. Dexamethasone particle size is controlled to 1–10 μm before compounding; larger drug particles settle during holding time and produce content uniformity failures. Release from ophthalmic implants in simulated vitreous fluid at 37°C can be sustained over 3–6 months in published PLGA 75:25 formulations, but B6007-1-specific release data is limited. Sterilization by ethylene oxide must be followed by outgassing until residual ethylene oxide and ethylene chlorohydrin meet ISO 10993-7:2008 limits for long-term ocular contact. Ethylene oxide processing at relative humidity above 60% is avoided because the acid-terminated polymer absorbs moisture and begins hydrolytic degradation before implantation. Critical failure modes on production lines include die swell, strand breakage under take-off tension, and yellowing of polymer at residence times longer than 5 minutes.

During ultrasonic spray coating of coronary and peripheral stent platforms, B6007-1 is dissolved in ethyl acetate or acetone/ethanol mixtures at 0.5–2.0 wt% and applied through ultrasonic nozzles operating at 40–120 kHz. Coating thickness per pass is maintained at 0.5–1.5 μm, and total PLGA layer thickness is limited to 1–5 μm to avoid strut bridging and mechanical brittleness during stent expansion. The acid-terminated 75:25 DL-PLG has lower solution viscosity than ester-capped grades, which improves atomization but increases sensitivity to humidity-driven phase separation on the stent surface. Coating mass per unit stent is measured by microbalance; uniformity is inspected by scanning electron microscopy or optical profilometry. Drug release of sirolimus or paclitaxel from thin PLGA films often produces a 24-hour burst of 20–40% because of the high surface-to-volume ratio; an outer topcoat of B6007-1 at 0.5–1.0 μm can reduce that burst by increasing diffusion path length. In vitro degradation testing per ASTM F1635-16 in phosphate-buffered saline at 37°C indicates that measurable mass loss begins between 4 and 8 weeks, while molecular weight reduction starts earlier. The use of B6007-1 with basic drugs such as sirolimus requires verification of acid–base interaction, because the carboxylate terminal groups may bind the drug and slow release in a manner that is not observed with ester-capped PLGA. Published data for B6007-1 in drug-eluting stent coatings is limited, so coating formulations require lot-specific acid number testing and release profiling under ISO 10993-5:2009 in vitro cytotoxicity assay.

When Scaffold Architecture Requires Low-Shear Leaching Without Residual Chloride Porogen

In salt-leached scaffold production, B6007-1 is dissolved in chloroform at 5–15% w/w and cast into molds packed with sodium chloride crystals of 100–400 μm. The solvent is evaporated at room temperature for 24–72 hours in a fume hood, followed by leaching in deionized water for 2–5 days with water changes every 12 hours. Residual chloride is monitored by conductivity or potentiometric titration, with release criteria based on implant site tolerance rather than a single universal value; published data for B6007-1-specific scaffolds is limited. Compression testing of porous constructs per ASTM D1621-16 gives moduli typically from 0.2 MPa to 5 MPa at porosities between 70% and 90%, which is lower than semicrystalline PLLA or PGA scaffolds and limits load-bearing bone applications. For electrospinning, B6007-1 is processed in hexafluoroisopropanol or chloroform/dimethylformamide 80:20 at 10–20 wt%, with applied voltage 12–25 kV, flow rate 0.5–3.0 mL/h, and tip-to-collector distance 10–20 cm. The resulting fiber diameter ranges from 200 nm to 1,000 nm, and residual hexafluoroisopropanol must be removed under vacuum because it is a Class 2 solvent. A critical operational boundary is the hydrated glass transition temperature of 75:25 DL-PLG: at body temperature in aqueous media, the amorphous matrix can soften, causing pore collapse and fiber shrinkage before tissue ingrowth is established. This behavior is expected from the 45–50°C dry glass transition, but B6007-1-specific hydrated Tg data is limited and should be measured by dynamic mechanical analysis in phosphate-buffered saline at 37°C for any scaffold design requiring mechanical competence beyond 4 weeks.

Calibrated Chemoembolization Microspheres and Arterial Shear Stability

Transarterial chemoembolization uses B6007-1 as a doxorubicin-loaded microsphere matrix with sieve-calibrated size fractions of 50–200 μm or 100–300 μm, with particle size confirmed by laser diffraction per ISO 13320:2020. The microspheres are suspended in nonionic contrast medium and saline and delivered through microcatheters of 2.0–2.7 Fr internal diameter. Because the 75:25 DL-PLG matrix is amorphous with a dry glass transition near 45–50°C, hydration at body temperature softens the particle shell; microspheres with insufficient molecular weight or residual solvent can flatten or fragment under arterial shear, causing off-target embolization. Doxorubicin is loaded by solvent evaporation or post-loading incubation, with encapsulation efficiency generally between 50% and 90% depending on drug-to-polymer ratio and pH of the aqueous phase; B6007-1-specific loading data is limited. The acid-terminal groups of B6007-1 interact with the primary amine of doxorubicin, which can reduce release rate but also depletes the acidic microclimate that otherwise accelerates PLGA degradation. In vitro release in phosphate-buffered saline at 37°C typically occurs over 1–7 days rather than weeks because of the high drug loading and short diffusion path, but this must be confirmed for B6007-1. Microsphere deformability is characterized by compression testing between parallel plates or by injection through a 2.0 Fr microcatheter at 1–5 mL/min and post-injection size distribution analysis. Control limits in embolization testing are commonly set at no more than 5% fragments below 20 μm after catheter transit; lots exceeding this threshold fail embolization risk assessment. Sterilization by gamma irradiation at 15–25 kGy may reduce molecular weight and accelerate release; if terminal sterilization is used, dose mapping per ISO 11137-1:2006 is required and release specifications must be revalidated on the sterilized lot.